| ²é¿´: 842 | »Ø¸´: 0 | ||||||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | ||||||
forest.zcÒø³æ (СÓÐÃûÆø)
|
[½»Á÷]
FDA ÍøÕ¾ä¯ÀÀ¼¼ÇÉ
|
|||||
ÔÚÆäËûÍøÕ¾ÉÏ×ªÔØµÄ£¬¿ÉÄÜ¶Ô³æ³æÃÇÓеãÓô¦¡£¡£¡£Ï²»¶¾Í¶àÖ§³Ö£¬¶àÆÀ¼Û![]() ![]() FDAÍøÕ¾ÊÇÓÉFDAÔÚInternetÉϽ¨Á¢µÄ£¬Ïò¹«ÖÚ¿ª·ÅµÄÐÅÏ¢·¢²¼Õ¾µã¡£±¾ÎĽéÉܸÃÕ¾µÄ½á¹¹²¢Ö÷Òª¿¼²ìÆäÖеÄҩѧÐÅÏ¢×ÊÔ´¡£¡¡¡¡ 1. FDAÖ÷Ò³½á¹¹ ¡¡¡¡¾·ÖÎö£¬¸ÃÖ÷Ò³¿É·Ö4¸öÇø£º¹¦ÄÜÇø¡¢Ö°ÔðÇø¡¢×¨ÒµÇø¡¢ÌáÊ¾Çø¡£Êµ¼ÊÊÇ4¸öÖ÷Ë÷Òý£¬±ãÓڷÿÍä¯ÀÀ¡£¸÷ÇøÏ໥¼äÓд󲿷ÖÊǽ»²æµÄ¡£ÏÖ·Ö±ð½éÉÜÈçÏ¡£ ¡¡¡¡1.1 ¹¦ÄÜÇø ÕâÊÇÒ»°ãÍøÕ¾Ö÷Ò³(°üÀ¨¸öÈ˺ÍÉÌÒµÍøÕ¾Ö÷Ò³)×î³£ÓõĽṹ£¬ÓÐ7¸öÀ¸Ä¿¡£ ¡¡¡¡1.1.1 ¸üÐÂÇé¿ö(what¡¯s new) ÌṩÐÂÔöÄÚÈݺͽüÆÚÐ޸ģ¬Ö÷ÒªÏòFDAÍøÕ¾µÄ¾³£·ÃÎÊÕß·þÎñ¡£ ¡¡¡¡1.1.2 ÍøÖ·Ä¿Â¼Index(FDA Web Site Index) ϵFDAϼ¶Ä¿Â¼µÄÖ÷Ì⣬°´×Öĸ˳ÐòÅÅÁС£Èç¡°¹ØÓÚFDA¡±(about FDA)¡¢Ëõд(Acronyms and Abbreviations)¡¢¸±×÷ÓÃ(Adverse Reactions)¡¢¹ËÎÊÍÅ(Advisory Committees)¡¢°®×̲¡(AIDS)¡¢ÀÏ»¯(Aging)¡¢Äê¼ø(Almanac)µÈµÈ¡£´ÖÂÔä¯ÀÀ¿ÉÒÔ¶ÔÍøÕ¾×ÜòÓиö´óÖÂÁ˽⡣µã»÷±êÌâ(ÈçAging)¼´¿É½øÈëÏà¹ØÄÚÈÝ¡£ ¡¡¡¡¡¡1.1.3 ËÑË÷Search(FAD Search) ÓÐÖúÓÚ¿ìËÙÕÒµ½ÍøÕ¾ÄÚËùÐèÐÅÏ¢¡£ÒÔ°¢ÎôÂåΤΪÀý£¬¼üÈëAcyclovir£¬ËÑË÷·¶Î§¡°Search All of FDA¡±£¬¿ÉÒÔ´Ó¸ÃÍøÕ¾ÅÓ´óµÄ47370ƪÎÄÏ×ÖÐÕÒµ½127ƪÏàÆ¥Åä¡£ËÑË÷½á¹û·Ö±ðÁгöÁËÕâЩÎÄÏ׵ĸÅÊö(Summary)ºÍÈë¿Ú£¬Èë¿ÚΪÀ¶É«µÄURLµØÖ·(http£º//......)£¬µã»÷ºó¿É½øÈëÕýÎÄ¡£Èç¹ûÖ»¹ØÐÄAcyclovirÔÚFDAÐÂÒ©ÉóÆÀÖеÄÇé¿ö£¬¿ÉÒÔÈ·¶¨ËÑË÷·¶Î§ÔÚÒ©Æ·ÉóÆÀºÍÑо¿ÖÐÐÄ(Center for Drug Evaluation and Research£¬CDER)£¬ÔòÆ¥ÅäÎÄÏ×¼õÖÁ71ƪ¡£ ¡¡¡¡¡¡1.1.4 ¸ßƵÎÊÌâFAQS(Frequently Asked Questions) ÒÔÎÊ´ðʽÁгöһЩ³£¼ûÎÊÌâ¡£·ÖΪ4´óÀࣺ¶¯ÎïÒ©¡¢»¯×±Æ·¡¢Ê³Æ·¡¢FDAÒ»°ãÎÊÌâ¡£ÒÔ¡°FDAÒ»°ãÎÊÌ⡱ΪÀýÓУ¬FDA×÷Óã¿×é³É£¿´¦Àí²»Á¼·´Ó¦·½Ê½£¿µÈµÈ¡£ ¡¡¡¡¡¡1.1.5 ¼Çʱ¾(Dockets) Ï൱ÓÚFDAµÄµµ°¸ÊÒ£¬°üÀ¨ÖØÒªÊ¼þ¡¢»áÒé¼Ç¼¡¢ÈÕ³ÌÁ÷Ë®ÕÊ¡£±ÊÕßÈÏΪ½ÏÖ÷ÒªµÄÓÐ2¸ö²¿·Ö£¬ÆäÒ»ÊÇ»áÒé¼Ç¼¹«¿ª(µã»÷ FDA Advisory Committees)£»Æä¶þÊÇÁª°î×¢²áµµ°¸(FDA Federal Register Documents)¡£Ëùν»áÒé¼Ç¼¹«¿ª£¬ÏµFDA¸÷¹ËÎÊÍŵĹ«¿ª»áÒé¼Ç¼¡£ÎªÁËÌåÏÖÐÂÒ©ÉóÆÀÖеĹ«¿ª¡¢¹«Õý£¬¸÷¹ËÎÊÍŵIJ¿·Ö»áÒé½²»°±»¼Ç¼ÔÚ°¸£¬ÉÏÍø¹«²¼¡£²»¹ýÕâЩ»áÒé¼Ç¼¶¯éüÈý°Ù¶àÒ³£¬ÊÇÃû·ûÆäʵµÄÎÄɽ»áº£¡£Èç¹ûÄãÖ»¹ØÐÄ»áÉÏר¼ÒÃÇÊÇÔõÑù̸µ½AcyclovirµÄ£¬ÔòÐèÓÃËÑË÷(¼û1.1.3)À´ËõС·¶Î§¡£¼üÈëAcyclovirºó£¬½«ËÑË÷·¶Î§ÏÞÓÚ¡°Dockets¡±£¬Ôò¿ÉÒÔ´Ó12233ƪDocketsÎÄÏ×Öв鵽29ƪÏàÆ¥Å䣬×Ðϸä¯ÀÀ¸ÅÊö(Summy)£¬ÕÒµ½»áÒé¼Ç¼£¬µã»÷Èë¿Ú£¬¼´¿ÉÖªµÀMr.XXÊÇÈçºÎÆÀ¼ÛAcyclovirÁË¡£²éAcyclovirµÄÁª°î×¢²áµµ°¸¿ÉͬÉϲÙ×÷¡£ÔÚÍøÉÏ¿ÉÒÔ¿´µ½AcyclovirµÄÉóÅú×ÊÁÏÔÎÄ(ͼƬÐÎʽ)£¬ÉõÖÁFDA¹ÙÔ±ÃÇÔÚAcyclovirÉóÅú×ÊÁÏÉÏÁʲݵļøÃû¡£ ¡¡¡¡¡¡1.1.6 ÍâÓï°æºÍ¹ú¼ÊÐÅÏ¢International(Foreign Language and Interational Information) Éæ¼°Ò»Ð©FDA·¨¹æµÄÍâÓï°æºÍFDAµÄ¹ú¼Ê¼äÐÒéºÍ»î¶¯¡£ÆäÖУ¬FDA·¨¹æÖÐÎİæµÄÐÅÏ¢²»¶à£¬Ö÷Òª½²Ê³Æ·ºÍ»¯×±Æ·½ø¿Ú¡£ÓÐÖ¾ÓÚ½«Ò©Æ·´òÈëÃÀ¹úÊг¡µÄÒ½Ò©¹«Ë¾£¬¿ÉÒÔÖØµãÑо¿¡°¹ú¼ÊÐÅÏ¢À¸¡±ÖС°ÈËÓÃÒ©Æ·¡±(Human Pharmaceutical Products:International Activities)£¬Æä·¨ÂÉÌõÎÄÊÇ×îеġ£ ¡¡¡¡1.1.7 ÁªÏµContact us(Communicating with FDA) Ò»¸öÎÊѶ´¦,²¢ÌáʾÔÚÎÊѶǰÓÐûÓп´¹ýÒ»Ð©Ö¸Ê¾ÅÆ,ͬʱÁгöÖ¸Ê¾ÅÆ.ÕÒ²»µ½,ÔÙдÐÅÁªÏµ. ¡¡¡¡1.2 Ö°ÔðÇø ÕâÊÇFDAÍøÕ¾ÍÆ³öµÄÖ÷Òª·ÖÀ෽ʽ£¬¾ùÅäÒÔͼ±ê£¬ÓÐ11´óÀ࣬°´¹ÜÀíÖ°Ôð·¶Î§·ÖÀà¡£ ¡¡¡¡1.2.1 ʳƷ(Foods) Á´ÏòFDAʳƷ°²È«ÓëÓªÑøÑ§ÖÐÐÄ£¬É漰ʳƷ²¿·Ö¡£Îª±£Ö¤Ê³Æ·°²È«ºÍºÏÀíÓªÑø·þÎñ¡£ ¡¡¡¡1.2.2 ÈËÓÃÒ©Æ·(Human Drugs) Á´ÏòFDAÒ©Æ·ÉóÆÀºÍÑо¿ÖÐÐÄ(CDER)£¬ÊÇҩѧÈËÔ±µÄÖØµã¹ØÐÄÀ¸Ä¿¡£ÑîÒ«Í¢[2]ÓÐһƪ½éÉÜFDAÍøÕ¾µÄÎÄÕÂÖ÷Ҫ̸¼°´ËÀ¸1997ÄêµÄÄÚÈÝ¡£ ¡¡¡¡1.2.3 ÉúÎïÖÆÆ·(Biologics) Á´ÏòFDAÉúÎïÖÆÆ·ÉóÆÀºÍÑо¿ÖÐÐÄ(CBER) ¡¡¡¡1.2.4 ÐóÓÃÒ©(Animal Drugs) Á´ÏòFDAÊÞÒ½Ò©ÖÐÐÄ¡£ ¡¡¡¡1.2.5 »¯×±Æ·(Cosmetics) Á´ÏòFDAʳƷ°²È«ÓëÓªÑøÑ§ÖÐÐÄ£¬Éæ¼°»¯×±Æ·²¿·Ö¡£ ¡¡¡¡1.2.6 Ò½ÁÆÆ÷еºÍ·ùÉäÎÀÉú(Medical Devices/Radiological Health) Á´ÏòFDAÒ½ÁÆÆ÷еºÍ·ùÉäÎÀÉúÖÐÐÄ(CDRH) ¡¡¡¡1.2.7 ÐÅÏ¢×ÔÓÉʹÓÃȨ(Freedom of information) 1996ÄêÓÐÒ»¸öÐÅÏ¢×ÔÓÉʹÓÃȨ·¨°¸µÄÐÞÕý°¸¡£FDAÍøÕ¾ÔÚÐÅÏ¢¿ª·ÅÉÏ×öÁ˺ܶ๤×÷¡£ ¡¡¡¡1.2.8 Õþ²ß·¨¹æ(Field Operations) Á´Ïò¹ÜÀíС×é°ì¹«ÊÒ£¬Ìṩ½ø³ö¿ÚÕþ²ß¡¢ºÏͬ¡¢ÐÒéµÈÏà¹Ø·¨¹æ¡£ ¡¡¡¡1.2.9 ¶ùͯÓëÑ̲Ý(Children and tobacco)FDAÖÆ¶¨µÄ±ÜÃâÏòÇàÉÙÄêÌṩÑ̲ݵ퍰¸¡£±¾À¸½éÉÜÏà¹Ø·¨ÂÉÌõÎĺÍÐÅÏ¢¡£ ¡¡¡¡1.2.10 ¶¾ÀíѧÑо¿(Toxicology Research) Á´ÏòFDA¹ú¼Ò¶¾ÀíѧÑо¿ÖÐÐÄ(NCTR)£¬±¾À¸Ïêϸ½éÉÜÁ˸ÃÖÐÐĵÄÈÎÎñ£¬ÒÇÆ÷É豸£¬ÈËÔ±×é³ÉµÈ£¬Õâ¶Ô¹úÄÚÒ©Àí»ò¶¾ÀíѧʵÑéÊҵıê×¼»¯½¨Éè¼°ÈçºÎÓëÊÀ½çͬ²½ÊǸöºÜºÃµÄ²Î¿¼¡£ ¡¡¡¡1.2.11 Ò½Ò©¼à²ì(Med Watch) ÓÖ³ÆFDAÒ½Ò©²úÆ·±¨¸æ³ÌÐò£¬ÓÃÓڼලºÍ±¨¸æÒÑÉÏÊвúÆ·µÄÑÏÖØ¸±×÷ÓúÍÎÊÌâ¡£¹úÄڵIJ»Á¼·´Ó¦¼à²ì±¨¸æÌåϵÓëÖ®ÀàËÆ¡£ ¡¡¡¡1.3 ÌØ±ðÐÅÏ¢(Special Information) ϵFDAÍøÕ¾ÍÆ³öµÄ¸¨Öú·ÖÀàÌåϵ¡£ÊÇÁíÒ»ÖÖÐÖúä¯ÀÀÕßÕÒµ½ËùÐèÄÚÈݵÄË÷Òý·½Ê½¡£ ¡¡¡¡1.3.1 Ïû·ÑÕß(Consumers) Ö÷ÒªÊÇÃæÏòÏû·ÑµÄһЩÀ¸Ä¿£¬Èç°®×̲¡ÁÙ´²ÊÔÑéÐÅÏ¢·þÎñ¡¢FDAÏû·ÑÕßÔÓÖ¾¡¢Èé·¿ÔìÓ°ÐÅÏ¢·þÎñ¡¢Ê³Æ·ÐÅÏ¢¡¢º£ÏÊÈÈÏß¡¢¹ØÓÚʳƷºÍÓªÑøµÄÖÒ¸æµÈµÈ¡£ ¡¡¡¡1.3.2 ¹¤Òµ(Industry) FDAÏòÒ½Ò©¹«Ë¾¡¢¹¤³§ÌṩµÄһЩ·¨ÂÉÐÅÏ¢£¬Èç½ø¿Ú³ÌÐò¡¢³ö¿Ú¡¢FDAÏà¹Ø·¨ÂÉ¡¢ÏòÁ®Õþ¹ÙÔ±¸æ·¢(Ombudsman)¡¢Áª°îµÇ¼Ç×¢²á¡¢FDAÒµÎñÖ¸µ¼µÈµÈ¡£ ¡¡¡¡1.3.3 ÎÀÉúרҵ(Health Professional) Óжà¸öרÀ¸£¬°üÀ¨ÁÙ´²ÈËÌåÊÔÑé±£»¤·¨Ôò¡¢¶¾Æ·¿ØÖƺÍÖÎÁÆ(ÃÀɳͪµÈ)¡¢¹ú¼ÊÎÀÉúÐж¯ºÍ×éÖ¯(WHOµÈ)¡¢×¨ÀûÏà¹Ø(ÃÀ¹úרÀûÉ̱ê¾Ö½éÉܵÈ)¡¢ÎÀÉúÍøÕ¾½éÉÜ(Èç¸ÐȾ¿ØÖÆÍøÕ¾¡¢Ò©Ñ§ÍøÕ¾¡¢¸¨ÖúÒ½ÁÆÍøÕ¾¡¢Ê³Æ·°²È«ÍøÕ¾µÈ£¬ÏµÁ´ÏòFDAÍøÕ¾ÍâµÄÆäËûÍøÕ¾) ¡¡¡¡1.3.4 »¼Õß(Patients) ÓÐһЩÀ¸Ä¿ÓëÏû·ÑÕßÀ¸Ä¿Öظ´¡£ËäÈ»FDA²¢·ÇרÃÅÃæÏòÒ½Ò©ÁìÓò£¬µ«Õâ·½Ãæ±Ï¾¹ÊÇÖØÒª²¿·Ö¡¢¹Êµ¥¶ÀÁÐÀ¸¡£ÄÚÈݰüÀ¨Óë°©Ö¢ºÍ°®×̲¡Ïà¹ØµÄרÌâ¡¢²¡È˲ÎÓëFDA»î¶¯µÄÖØÒªÐÔ˵Ã÷¡¢³£¼ûÎÊÌâºÍÆÀÂÛ¡¢FDAÓ벡È˵Ľ»Á÷µÈ¡£ ¡¡¡¡1.3.5 ÖÝÓëµØ·½»ú¹¹(State &Local officials) ϵÁª°îÓë¸÷ÖÝFDA»ú¹¹µÄ¹ØÏµ£¬¸÷ÖÝFDA»ú¹¹¼°×¨¼Ò½éÉÜ¡£ ¡¡¡¡1.3.6 Å®ÐÔ(Woman) ÌṩÓëÅ®ÐÔ½¡¿µÈ粸ÈéµÈÏà¹ØµÄÄÚÈݼ°Á´½Ó¡£ ¡¡¡¡1.3.7 ¶ùͯ(Kids) ÌṩÓë¶ùͯ½¡¿µÏà¹ØµÄÄÚÈݼ°Á´½Ó¡£ ¡¡¡¡1.4 ÌáÊ¾Çø ¼ÐÔÚ¸÷ÇøÖ®¼ä£¬ÊÇFDAÍøÕ¾ÈÏΪֵµÃÍÆ¼öµÄÖØÒªÄÚÈݺÍÁ´½Ó¡£Èç2000ÄêÎÊÌâ(year 2000)¡¢»¶Ó´Ê(Welcome to Internet FDA)¡¢FDAÏÖ´ú»¯·¨°¸(FDA Modernization ACT)£»¹ú¼ÊÀÏÈËÄꣻ HHS (Department of health and human services)µÈ¡£HHSÊÇÒ»¸öÓëFDAÃÜÇÐÏà¹ØµÄ²¿ÃÅÍøÕ¾£¬²¢·ÇFDAÍøÕ¾ÖÐÒ»¸öÀ¸Ä¿£¬½á¹¹ÅÓ´ó½«ÁíÎĽéÉÜ¡£ ¡¡¡¡¹ØÓÚFDAÍøÕ¾Ö÷Ò³µÄ½á¹¹¾Í½éÉܵ½ÕâÀï¡£¾¹éÄÉ£¬FDA¹ÜÀí·¶Î§Éæ¼°Ò©Æ·µÄÖ÷ÒªÓÐ3¸ö·½Ã棺¢ÙÐÂÒ©Åú×¼£»¢ÚÐÂҩ˵Ã÷ÊéµÄÅú×¼¼°Ð޸컢ÛÒ©Æ·Éú²ú±ê×¼µÄ°ä²¼¡£Òò´Ë£¬Õâ¸öÍøÕ¾µÄҩѧÐÅÏ¢×ÊÔ´Ö÷Òª¼¯ÖÐÔÚÕâÈý¸ö·½Ãæ¡£ ¡¡¡¡2£®ÍøÉÏFDAµÄҩѧÐÅÏ¢×ÊÔ´ ¡¡¡¡ÎªÁËÈùúÄÚҩѧ¹¤×÷ÕßÄÜ·½±ãµØÀûÓÃFDAÍøÕ¾ÖеÄҩѧÐÅÏ¢×ÊÔ´£¬¾·´¸´±È½Ï£¬ÎÒÃÇÖØµãÍÆ¼öÒÔϼ¸¸öÀ¸Ä¿¡£ ¡¡¡¡2.1 ³ÈƤÊé(Approved Drug Products£¬µç×Ó°æ)[3] Ó¦¸Ã˵£¬ÕâÊÇFDAÍøÕ¾µÄÉæ¼°Ò©Ñ§×»ª²¿·Ö£¬ÊǹúÄÚÐÂÒ©Ñо¿¹¤×÷Õß¡¢ÌرðÊǰÑÎÕ¹úÄÚÍâҩѧ½øÕ¹µÄÖÇÄÒÃÇ×î¹ØÐĵIJ¿·Ö¡£¸ÃÀ¸Ä¿¸üкܿ죬ÇÒϵͳ¡¢È¨Íþ¶øÈ«Ãæ¡£½øÈë³ÈƤÊéÍøÒ³ºó£¬¿ÉÒÔ¸ù¾Ý4¸öÏßË÷À´²éѰ(»îÐԳɷݡ¢×¨ÓÐÃû¡¢ÉêÇëÈË¡¢ÉêÇëºÅ)£¬ÒÔµã»÷¡°»îÐԳɷݡ±ÎªÀý£¬½øÈëÏÂÒ»Ò³£¬¼üÈë¡°Acyclovir¡±£¬Ò³ÃæÌá³öµÚ¶þ´ÎÑ¡Ôñ£ºRx(´¦·½Ò©)¡¢OTC(·Ç´¦·½Ò©)¡¢Disc(·ÏÖ¹Ò©)¡£Ñ¡ÔñRx£¬µã»÷¡°Ìá½»¡±(Submit Query)£¬¿ÉµÃµ½FDAÒÑÅú×¼µÄ57¸öAcyclovir´¦·½Ò©ÅúÎĵÄÁÐ±í£¬ÔÙµã»÷×ó²àµÚÒ»À¸µÄÉêÇëºÅ(Appl.No)£¬ÔòµÃµ½¸ÃÆ·ÖֵĽϾßÌåÇé¿ö£¬°üÀ¨»îÐԳɷݡ¢¼ÁÐÍ¡¢ÓÃҩ;¾¶¡¢×¨ÓÐÃû¡¢ÉêÇëÈË¡¢¼ÁÁ¿¡¢ÉêÇëºÅ¡¢²úÆ·ºÅ¡¢Åú×¼ÈÕÆÚ¡¢×¨ÀûÅÅËûÐÔ¡¢ÖÎÁƵÈЧÐÔ´úÂëµÈ£»µã»÷AcyclovirµÄ¡°OTCÒ©¡±£¬ÎÞÆ¥Å䣻µã»÷¡°Disc¡±£¬¿ÉµÃÖªÈý¸öAcyclovirÆ·ÖÖÒѱ»È¡ÏûÅúÎĺš£ ¡¡¡¡ÓûÁ˽â×î½üÒ»ÖÜ»òÒ»ÔÂFDAÅú×¼Ò©ÎïÇé¿ö£¬¿ÉÒԲο¼ÁíÒ»¸öÀ¸Ä¿-FDAÅú×¼Ò©Æ·Áбí(FDA Drug Approval list)£¬¸ÃÀ¸Ä¿Ã¿ÖܸüУ¬·ÖÊ×´´ÐÂÒ©¡¢Ê×´´ÐÂÒ©ºË×¼¡¢¹¦Ð§ÐÂÔöµÈÈý¸öÀ¸Ä¿£¬°´Äê¡¢ÔÂÁгö¡¢×îпɲ鵽1ÖÜǰµÄÅú×¼Çé¿ö¡£ ¡¡¡¡ÉÏÊöÁ½À¸ÌṩµÄÅú×¼ÐÅÏ¢½Ï¼òµ¥£¬ÈçÏëÁ˽â¸üÏêϸµÄÅú×¼ÐÂÒ©ÐÅÏ¢£¬Ôò¿ÉÒÔ½øÈëFDAÅú×¼Ò©Æ·ÐÅÏ¢°ü(FDA Drug Approval Packages)[5]£¬µã»÷Äê¶È(Èç99Äê)£¬½øÈë99Äê·ÖÀ¸¡£²éѯ½á¹û°´ÉÌÆ·Ãû×Öĸ˳ÐòÅÅÁС£²éµ½¸ÐÐËȤµÄÆ·ÖÖ(ÈçAcyclovir)ºó£¬µã»÷±íÖС°ËµÃ÷Ê顱(label)»ò×ÛÊö(Review)¼´¿É¡£ ¡¡¡¡2.2 Ïû·ÑÕßÒ©Æ·ÐÅÏ¢(Consumer Drug Information)[6] ÃæÏòÏû·ÑÕßÉèÁ¢£¬ÄÚÈÝÓжþÀ¸£¬µÚÒ»À¸ÊǸÕÅú×¼µÄÐÂÒ©ÐÅÏ¢£¬Õⲿ·ÖÓë³ÈƤÊéÄÚÈÝÏàͬ£¬µ«Ö»ÏÞÓÚÐÂÆ·ÖÖ¡£µÚ¶þÀ¸ÊÇÎÊ´ð£¬ÒÔǰ¶Îʱ¼äÔÚ¹úÄÚ³´×÷µÄ¡°Î°¸ç¡±(Viagra)ΪÀý£¬ÓÐÒÔϼ¸¸öÎÊ´ð£ºÎ°¸çµÄÓÃ;£¿Ë²»¿ÉʹÓã¿ÉÏÊÐÓ¦ÓúóËù³öÏÖÎÊÌâµÄ¹«¸æ£»¹ØÓÚÑÏÖØ·´Ó¦µÄÌØ±ð¾¯¸æ£»Ò»°ãÐÔ·À·¶£»Î°¸çµÄÓ÷¨£¿¿ÉÄܵĸ±×÷Ó㿸üÏêϸ×ÊÁϵÄÁ´½á(Á´Ïò˵Ã÷Êélabel)¡£ÒòΪÕâÊÇFDAÃæÏòÏû·ÑÕß¹«²¼µÄ£¬¹Ê¼ÈÓÐȨÍþÐÔ£¬ÓÖͨË×Ò×¶®¡£¶ÔҽԺҩʦ»Ø´ð²¡È˵ÄÒ©Æ·ÐÅÏ¢×Éѯ£¬Óкܴó²Î¿¼ÒâÒå¡£Òª»Ø´ð¸ü¶àµÄÎÊÌâ¿ÉÒÔ²éÔÄ˵Ã÷Êé¡£ ÕâÀïµÄ¡°ËµÃ÷Ê顱ÄÚÈÝÊ®·ÖÏêϸ(ÈçViagraÓÐ18Ò³)£¬Ô¶±È¹úÄÚҩƷ˵Ã÷ÊéÏêϸ£¬ËäÈ»»¼Õß¿ÉÄÜÓÐЩÔĶÁ²»±ã£¬µ«¶Ôҩʦ¶øÑÔÊǷݺܲ»´íµÄ×ÊÁÏ¡£ ¡¡¡¡2.3 FDAҽѧ¹«¸æ(FDA Medical Bulletin)[7] λÓÚCDERÖС°ÐÂÎÅÀ¸¡±(what¡¯s happening)£¬°´Äê¶È»ã×ÜÉÏÍø£¬Ä¿Ç°¿ÉÔÚÍøÉÏ¿´µ½96-98Ä겿·ÖÆÚ¿¯¡£Õâ¸ö¿¯ÎïÔÚ¶àÊýҽѧԺУͼÊé¹ÝÖв»ºÃÕÒ¡£ÉÏÓÐFDAÖØÒªÐÅÏ¢£¬´ÓÊÂÒ½Ò©¹¤ÒµÑо¿µÄ¿ÆÑÐÈËÔ±¿ÉÒÔ´ÓÖеõ½ºÜ¶àÆô·¢¡£ ¡¡¡¡2.4 FDAÏû·ÑÕßÔÓÖ¾(FDA Consumer Magazine)[8] λÖÃͬ´¦CDER¡°ÐÂÎÅÀ¸¡±¡£ÕâÊÇÒ»¸öµç×Ó°æÔÓÖ¾¡£ÃæÏòÏû·ÑÕߣ¬µ«ÖÊÁ¿¼«¸ß¡£¸ÃÆÚ¿¯ÆÚÊýÈ«¡¢ÄÚÈÝС¢ÉÏÍø¿ì¡£±ÊÕß7ÔÂ1ÈÕÉÏÍø¼´¿É¿´µ½µ±ÔÂÆÚ¿¯¡£±¾ÆÚÄÚÈÝÓУºÈé°©µÄÐÂÁÆ·¨¡¢AIDSµÄ¼¦Î²¾ÆÁÆ·¨¡¢ºÏÀíÓÃÒ©½µÑªÑ¹¡¢Ñ¿ÁÛ²¡µÄ¿ìËÙÒ½ÖΡ¢¹ØÓÚ¼ò»¯ËµÃ÷ÊéµÄºôÓõµÈ¡£¸ÃÔÓÖ¾µÄÁíÒ»¸öÀ¸Ä¿ÊDz¿ÃŻ£¬°üÀ¨µ÷²é±¨¸æ¡¢·¨°¸¡¢¸üеȡ£Ïû·ÑÕßÔÓÖ¾ÊǺê¹ÛÁ˽âÃÀ¹úÒ©Æ··¢Õ¹Ç°ÑصIJ»¿É¶àµÃµÄ´°¿ÚÖ®Ò»¡£ ¡¡¡¡2.5 ¡°Top drug news¡± λÓÚ¡°Ò©Æ·ÐÅÏ¢¡±À¸¶¥À¸£¬Ö÷Òª½éÉÜÈÈÃÅÆ·ÖÖ£¬Ï൱ÓÚ±¨Ö½µÄÍ·°æÍ·Ìõ£¬±¾ÆÚ½éÉÜÁËÈý¸öÒ©Æ·£º¢ÙCenestinµÄÅú×¼¡£Ïµ½áºÏ´Æ¼¤ËØ£¬¸ÃÒ©ÔÚÁíÒ»¸öÍøÕ¾RxlistÖÐλ¾Ó98ÄêTop200Ö®Êס£¢ÚTrovantµÄ¸Î¶¾ÐÔÖҸ档ϵһÖÖ¿¹ÉúËØ¡£¢Ûΰ¸çÐÅÏ¢(Viagra)¡£Óë¡°Ïû·ÑÕßÐÅÏ¢¡±Ëù½éÉÜViagraÏà±È£¬¸üΪרҵ»¯¶øÈ«Ãæ¡£¹úÄÚ³§¼ÒÈç¶Ô´Ë¸ÐÐËȤ£¬²»·Áµ½´Ë²Î¿¼Ò»ÏÂÓÐÎÞ×îÐÂÐÅÏ¢ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ľÓгæ | Ò½Ò©Ñз¢ | CDE-CTD |
» ²ÂÄãϲ»¶
291Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
309Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
085601²ÄÁϹ¤³ÌÕÒµ÷¼Á
ÒѾÓÐ10È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
Ò»Ö¾Ô¸ÄϺ½ 335·Ö | 0856 | GPA 4.07 | ÓпÆÑоÀú
ÒѾÓÐ6È˻ظ´
070305¸ß·Ö×Ó»¯Ñ§ÓëÎïÀí 304·ÖÇóµ÷¼Á
ÒѾÓÐ11È˻ظ´
»·¾³¹¤³Ì 085701£¬267Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸Ö£ÖÝ´óѧ£¬080500ѧ˶£¬×Ü·Ö317·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
¿¼Ñе÷¼Á
ÒѾÓÐ5È˻ظ´
ÄϾ©´óѧ»¯Ñ§µ÷¼Á
ÒѾÓÐ8È˻ظ´















»Ø¸´´ËÂ¥
